This document provides an agenda for the "Global Pharmaceuticals Research & Manufacturing India 2008" conference taking place on December 3rd and 4th, 2008 in Mumbai, India. The conference will focus on key issues in pharmaceutical research and manufacturing in India, including outsourcing clinical trials to India, evaluating implications of moving R&D offshore, emerging trends in biotechnology, and evolving partnering and business models. Topics to be covered include drug development, clinical research, regulation, quality management, and contract manufacturing. The event is aimed at senior executives in the pharmaceutical industry and will feature presentations and panels with industry leaders.
This document discusses outsourcing in the pharmaceutical industry. It defines outsourcing as transferring portions of work to outside suppliers in order to reduce costs. The main types of outsourcing in pharma include research and development, clinical trials, manufacturing, packaging, and sales/marketing. The key drivers of outsourcing are focusing on core strengths, reducing costs, and decreasing time to market. While outsourcing provides advantages like cost reductions, it also presents risks such as loss of managerial control and internal talent. Overall, outsourcing allows pharma companies to exploit new drug technologies while solving problems, though successful management of vendor relationships is critical.
This document discusses project management in the pharmaceutical industry. It covers topics such as the importance of planning, types of planning, steps involved in planning, elements of planning, challenges, project implementation, and measuring project success. It also provides a case study on Eli Lilly and how the company overcame challenges through increased R&D spending, collaborations, and implementing open innovation strategies.
Clinical Trial Costs in Emerging Geographies - Stephen PorterTTC, llc
1. VDDI Pharmaceuticals utilizes a virtual business model to outsource drug development functions like preclinical and clinical trials to reduce costs.
2. Xemilofiban is a drug product that has already undergone Phase II and III trials and has proven safety and efficacy advantages over existing products.
3. Conducting multi-center Phase II and III trials in China provides an opportunity to secure Chinese regulatory approval and save 2-4 years bringing the drug to market in China compared to other regions.
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketMarketResearch.com
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years. Contract Research Organizations (CROs) and other entities can expect growing demand for their services.
The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information's Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
Global supply chain in ranbaxy paonta sahib manufacturing facilityAnkur Srivastava
This is a project report made by me on the Global Supply Chain Process of Ranbaxy Laboratories Ltd., one of the world's largest Pharmaceutical Manufacturers; and its impact on its Global Business. The related study was done in the year 2011 and report was prepared then.
This document discusses the rise of contract research organizations (CROs) that conduct clinical trials and other services on behalf of pharmaceutical companies. It notes that CROs have grown dramatically since the 1980s as drug companies increasingly outsource research to cut costs. While CROs claim to provide independent research, some experts argue they still face conflicts of interest since they rely on industry funding. The document also examines how CROs are expanding globally and investing in new technologies to increase their service capacity and distinguish themselves from competitors in a growing market.
Eli Lilly and Company needs to decide on the type of manufacturing facility to build for new pharmaceutical products. Three options are considered: specialized, flexible, or hybrid facilities. A hybrid facility that uses flexible manufacturing initially and specialized facilities later for high demand products is recommended. This allows for reduced lead times early on while minimizing costs through specialized high utilization facilities later.
Healthcare Contract Research Organization (CRO) MarketTom Clark
Global Healthcare Contract Research Organization (CRO) Market is expected to reach USD 51.3 billion by 2024 with CAGR of 6.5% over the future period as the scope and its applications are rising enormously across the globe.
This document discusses outsourcing in the pharmaceutical industry. It defines outsourcing as transferring portions of work to outside suppliers in order to reduce costs. The main types of outsourcing in pharma include research and development, clinical trials, manufacturing, packaging, and sales/marketing. The key drivers of outsourcing are focusing on core strengths, reducing costs, and decreasing time to market. While outsourcing provides advantages like cost reductions, it also presents risks such as loss of managerial control and internal talent. Overall, outsourcing allows pharma companies to exploit new drug technologies while solving problems, though successful management of vendor relationships is critical.
This document discusses project management in the pharmaceutical industry. It covers topics such as the importance of planning, types of planning, steps involved in planning, elements of planning, challenges, project implementation, and measuring project success. It also provides a case study on Eli Lilly and how the company overcame challenges through increased R&D spending, collaborations, and implementing open innovation strategies.
Clinical Trial Costs in Emerging Geographies - Stephen PorterTTC, llc
1. VDDI Pharmaceuticals utilizes a virtual business model to outsource drug development functions like preclinical and clinical trials to reduce costs.
2. Xemilofiban is a drug product that has already undergone Phase II and III trials and has proven safety and efficacy advantages over existing products.
3. Conducting multi-center Phase II and III trials in China provides an opportunity to secure Chinese regulatory approval and save 2-4 years bringing the drug to market in China compared to other regions.
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketMarketResearch.com
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years. Contract Research Organizations (CROs) and other entities can expect growing demand for their services.
The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information's Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
Global supply chain in ranbaxy paonta sahib manufacturing facilityAnkur Srivastava
This is a project report made by me on the Global Supply Chain Process of Ranbaxy Laboratories Ltd., one of the world's largest Pharmaceutical Manufacturers; and its impact on its Global Business. The related study was done in the year 2011 and report was prepared then.
This document discusses the rise of contract research organizations (CROs) that conduct clinical trials and other services on behalf of pharmaceutical companies. It notes that CROs have grown dramatically since the 1980s as drug companies increasingly outsource research to cut costs. While CROs claim to provide independent research, some experts argue they still face conflicts of interest since they rely on industry funding. The document also examines how CROs are expanding globally and investing in new technologies to increase their service capacity and distinguish themselves from competitors in a growing market.
Eli Lilly and Company needs to decide on the type of manufacturing facility to build for new pharmaceutical products. Three options are considered: specialized, flexible, or hybrid facilities. A hybrid facility that uses flexible manufacturing initially and specialized facilities later for high demand products is recommended. This allows for reduced lead times early on while minimizing costs through specialized high utilization facilities later.
Healthcare Contract Research Organization (CRO) MarketTom Clark
Global Healthcare Contract Research Organization (CRO) Market is expected to reach USD 51.3 billion by 2024 with CAGR of 6.5% over the future period as the scope and its applications are rising enormously across the globe.
Dear all,
I have tried putting down my view-points on benefits of Project Management system in Pharmaceutical Industry...
Please let me know what do you think.
Regards,
Megha Thakkar
Complex Generics Overview - Outlooks and ChallengesSanjay Chaturvedi
The document summarizes a presentation given at the 5th Regulatory Conference on the evolving global regulatory environment. The presentation discusses complex generics known as "SuperGenerics", which are improved versions of existing drugs that have lost patent protection. They include modified release formulations, transdermal patches, and other delivery methods. SuperGenerics provide advantages like quicker action, fewer side effects, and more convenient dosing. Global pharmaceutical companies are placing significant focus and investment on SuperGenerics as a way to gain competitive advantages and higher profits in the generic drug market. The development of SuperGenerics presents opportunities but also regulatory and clinical challenges.
Pathways to Efficient Drug Development - Advances in Modeling and Simulation ...ReportsnReports
The report examines ways the pharmaceutical industry is seeking to improve efficiency in drug development given rising costs and other challenges. It explores areas like precompetitive research collaboration, use of modeling and simulation in clinical trials, and novel business models. The 66-page report analyzes these topics based on primary interviews and secondary research to identify key innovations and their potential to help companies develop drugs more effectively.
Introduction to pharmaceutical industry & clinical researchBhaswat Chakraborty
This document provides an introduction to the global pharmaceutical market and clinical research environment. It discusses the significant growth expected in the global pharmaceutical market between 2010-2013. It also outlines the top 20 pharmaceutical companies by revenue. The document then discusses the Indian pharmaceutical market, noting that India is a leader in generic drugs and active pharmaceutical ingredients. It provides an overview of the top 10 pharmaceutical companies in India by revenue. The document also discusses the growth of the Indian domestic market. It introduces the dynamic continuum of drug discovery and provides definitions and descriptions of clinical research, phases of clinical trials, and the largest registry of clinical trials. It discusses opportunities for India in clinical research outsourcing and the growth of the CRO market in India.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Outsourcing is a Cost-effective strategy when used properly and at present is gaining more and more importance. Here's a short presentation about the importance of outsourcing in Clinical research.
Role of CRO’s in Medical Innovation and Drug DevelopmentJohn Douglas
Critical medical conditions such as new threats from chronic diseases and their debilitating conditions require quick responses and consistent attempts on a global level. Therefore, when the medical equipment and pharmaceutical biotechnology companies are in need to introduce efficient and effective drugs faster to the market, that is the time when they also need partners who are able to collaborate and assure them effortless development and service delivery.
Challenges in regulatory filing of generic products in Europe and Malyasia.rkreddy98666
The document discusses the challenges and processes for regulatory filing of generic products in Europe and Malaysia. It provides definitions of key terms like generic products and innovator products. The major differences between innovator and generic products are described. The generic drug development process and requirements are outlined. The various procedures for marketing authorization of generics in Europe like centralized, decentralized, national and mutual recognition procedures are summarized. The document also provides an overview of the ASEAN Common Technical Document (ACTD) format and lists the typical documents required for a generic drug filing in Malaysia.
This presentation covers the Introduction to Healthcare & different Products, Role of Pharmaceutical in Healthcare, Drug Details, What a drug is made of ?, Classification of drugs, Product Life Cycle of a Drug, Drug Development Phases, Regulatory Framework & various Regulatory Bodies
ReportsnReports – Point of Care Diagnostic Testing World MarketsReportsnReports
Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. This outsourcing has grown as drug development has become more complex.
- When deciding whether and how to use a CRO, companies consider tactical, maximal, or strategic outsourcing based on their internal resources. Selecting the right CRO requires evaluating their capabilities, compatibility with the sponsor's needs, and costs.
- Managing the sponsor-CRO relationship is critical to ensure success. This involves clearly defining roles and responsibilities, establishing performance metrics,
ARSTAT Pharmaceuticals is seeking investors and partners as it prepares for an IPO. It has a pipeline of four first-in-class women's health products targeting large markets, including potential blockbusters Nuvocept and Premring. Nuvocept is a novel oral contraceptive designed for overweight/obese women, a major unmet need. Premring is a medicated vaginal ring to treat uterine fibroids and endometriosis. Both are in late-stage development and have the potential for high returns within 3-3.5 years due to ARSTAT's experienced team and advanced, low-risk programs. The company aims to complete development and sell assets at a valuation of at least $180M
Interview pharmatutor: Pharmacy Education and Pharmaceutical IndustryBhaswat Chakraborty
The document discusses pharmacy education in India and opportunities for its improvement. It notes that while theoretical education is generally good, practical training varies significantly between institutions. It also notes differences from Western pharmacy programs which are more patient-centric and clinically oriented, while Indian programs focus more on industrial orientation. Overall pharmacy education meets current employer needs but there is room for growth, particularly in clinical and practical training at the undergraduate level.
Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory ...ReportsnReports
This report analyzes biopharmaceutical manufacturing and the contract manufacturing industry in India, China, and South Korea. It provides an overview of regulatory frameworks, infrastructure support, and funding that have created an environment conducive to industry growth. The report details market sizes and forecasts through 2016, as well as trends such as outsourcing and partnerships between pharmaceutical companies and contract manufacturers in these regions. It also profiles major players and assesses factors like operating costs, skills, and government initiatives that affect industry competitiveness in each country.
Generic drug companies are relying heavily on qualified contract research organizations (CROs) to accelerate their development processes and be first to market after patents expire on branded drugs. CROs provide expertise across development areas like preclinical research, clinical trials management, bioequivalence studies, analytical testing, and ANDA submissions that help generics meet tight deadlines. Successfully demonstrating bioequivalence through bioavailability and dissolution studies is key for regulatory approval and requires CROs with strong laboratory capabilities and experience navigating regulatory requirements.
This presentation discusses Antares Pharma's OTREXUP product and pipeline. OTREXUP is a methotrexate auto-injector that was recently approved for treatment of rheumatoid arthritis, psoriasis, and juvenile rheumatoid arthritis. Antares has also partnered with LEO Pharma for promotion of OTREXUP in dermatology. The presentation provides an overview of Antares' launch plan for OTREXUP and discusses its VIBEX QS Testosterone product which is currently in development for treatment of low testosterone.
This document discusses broad opportunities in pharmacy careers. It notes that the global pharmaceutical market is significant and growing at around 6% annually, reaching over $1.4 trillion by 2018. India represents the 3rd largest pharmaceutical market by volume and is a leader in generic drugs. There are over 100 US FDA-approved manufacturing facilities in India. Career opportunities for pharmacists exist across pharmaceutical industry roles in discovery, research and development, production, marketing, administration, academia, consulting, regulation, and more. Successful careers require not just academic skills but also teamwork, communication, leadership abilities and stress management.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
Dear all,
I have tried putting down my view-points on benefits of Project Management system in Pharmaceutical Industry...
Please let me know what do you think.
Regards,
Megha Thakkar
Complex Generics Overview - Outlooks and ChallengesSanjay Chaturvedi
The document summarizes a presentation given at the 5th Regulatory Conference on the evolving global regulatory environment. The presentation discusses complex generics known as "SuperGenerics", which are improved versions of existing drugs that have lost patent protection. They include modified release formulations, transdermal patches, and other delivery methods. SuperGenerics provide advantages like quicker action, fewer side effects, and more convenient dosing. Global pharmaceutical companies are placing significant focus and investment on SuperGenerics as a way to gain competitive advantages and higher profits in the generic drug market. The development of SuperGenerics presents opportunities but also regulatory and clinical challenges.
Pathways to Efficient Drug Development - Advances in Modeling and Simulation ...ReportsnReports
The report examines ways the pharmaceutical industry is seeking to improve efficiency in drug development given rising costs and other challenges. It explores areas like precompetitive research collaboration, use of modeling and simulation in clinical trials, and novel business models. The 66-page report analyzes these topics based on primary interviews and secondary research to identify key innovations and their potential to help companies develop drugs more effectively.
Introduction to pharmaceutical industry & clinical researchBhaswat Chakraborty
This document provides an introduction to the global pharmaceutical market and clinical research environment. It discusses the significant growth expected in the global pharmaceutical market between 2010-2013. It also outlines the top 20 pharmaceutical companies by revenue. The document then discusses the Indian pharmaceutical market, noting that India is a leader in generic drugs and active pharmaceutical ingredients. It provides an overview of the top 10 pharmaceutical companies in India by revenue. The document also discusses the growth of the Indian domestic market. It introduces the dynamic continuum of drug discovery and provides definitions and descriptions of clinical research, phases of clinical trials, and the largest registry of clinical trials. It discusses opportunities for India in clinical research outsourcing and the growth of the CRO market in India.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Outsourcing is a Cost-effective strategy when used properly and at present is gaining more and more importance. Here's a short presentation about the importance of outsourcing in Clinical research.
Role of CRO’s in Medical Innovation and Drug DevelopmentJohn Douglas
Critical medical conditions such as new threats from chronic diseases and their debilitating conditions require quick responses and consistent attempts on a global level. Therefore, when the medical equipment and pharmaceutical biotechnology companies are in need to introduce efficient and effective drugs faster to the market, that is the time when they also need partners who are able to collaborate and assure them effortless development and service delivery.
Challenges in regulatory filing of generic products in Europe and Malyasia.rkreddy98666
The document discusses the challenges and processes for regulatory filing of generic products in Europe and Malaysia. It provides definitions of key terms like generic products and innovator products. The major differences between innovator and generic products are described. The generic drug development process and requirements are outlined. The various procedures for marketing authorization of generics in Europe like centralized, decentralized, national and mutual recognition procedures are summarized. The document also provides an overview of the ASEAN Common Technical Document (ACTD) format and lists the typical documents required for a generic drug filing in Malaysia.
This presentation covers the Introduction to Healthcare & different Products, Role of Pharmaceutical in Healthcare, Drug Details, What a drug is made of ?, Classification of drugs, Product Life Cycle of a Drug, Drug Development Phases, Regulatory Framework & various Regulatory Bodies
ReportsnReports – Point of Care Diagnostic Testing World MarketsReportsnReports
Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. This outsourcing has grown as drug development has become more complex.
- When deciding whether and how to use a CRO, companies consider tactical, maximal, or strategic outsourcing based on their internal resources. Selecting the right CRO requires evaluating their capabilities, compatibility with the sponsor's needs, and costs.
- Managing the sponsor-CRO relationship is critical to ensure success. This involves clearly defining roles and responsibilities, establishing performance metrics,
ARSTAT Pharmaceuticals is seeking investors and partners as it prepares for an IPO. It has a pipeline of four first-in-class women's health products targeting large markets, including potential blockbusters Nuvocept and Premring. Nuvocept is a novel oral contraceptive designed for overweight/obese women, a major unmet need. Premring is a medicated vaginal ring to treat uterine fibroids and endometriosis. Both are in late-stage development and have the potential for high returns within 3-3.5 years due to ARSTAT's experienced team and advanced, low-risk programs. The company aims to complete development and sell assets at a valuation of at least $180M
Interview pharmatutor: Pharmacy Education and Pharmaceutical IndustryBhaswat Chakraborty
The document discusses pharmacy education in India and opportunities for its improvement. It notes that while theoretical education is generally good, practical training varies significantly between institutions. It also notes differences from Western pharmacy programs which are more patient-centric and clinically oriented, while Indian programs focus more on industrial orientation. Overall pharmacy education meets current employer needs but there is room for growth, particularly in clinical and practical training at the undergraduate level.
Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory ...ReportsnReports
This report analyzes biopharmaceutical manufacturing and the contract manufacturing industry in India, China, and South Korea. It provides an overview of regulatory frameworks, infrastructure support, and funding that have created an environment conducive to industry growth. The report details market sizes and forecasts through 2016, as well as trends such as outsourcing and partnerships between pharmaceutical companies and contract manufacturers in these regions. It also profiles major players and assesses factors like operating costs, skills, and government initiatives that affect industry competitiveness in each country.
Generic drug companies are relying heavily on qualified contract research organizations (CROs) to accelerate their development processes and be first to market after patents expire on branded drugs. CROs provide expertise across development areas like preclinical research, clinical trials management, bioequivalence studies, analytical testing, and ANDA submissions that help generics meet tight deadlines. Successfully demonstrating bioequivalence through bioavailability and dissolution studies is key for regulatory approval and requires CROs with strong laboratory capabilities and experience navigating regulatory requirements.
This presentation discusses Antares Pharma's OTREXUP product and pipeline. OTREXUP is a methotrexate auto-injector that was recently approved for treatment of rheumatoid arthritis, psoriasis, and juvenile rheumatoid arthritis. Antares has also partnered with LEO Pharma for promotion of OTREXUP in dermatology. The presentation provides an overview of Antares' launch plan for OTREXUP and discusses its VIBEX QS Testosterone product which is currently in development for treatment of low testosterone.
This document discusses broad opportunities in pharmacy careers. It notes that the global pharmaceutical market is significant and growing at around 6% annually, reaching over $1.4 trillion by 2018. India represents the 3rd largest pharmaceutical market by volume and is a leader in generic drugs. There are over 100 US FDA-approved manufacturing facilities in India. Career opportunities for pharmacists exist across pharmaceutical industry roles in discovery, research and development, production, marketing, administration, academia, consulting, regulation, and more. Successful careers require not just academic skills but also teamwork, communication, leadership abilities and stress management.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
This document provides information about the 5th Pharmacovigilance Congregation conference taking place on November 20th, 2013 in Mumbai, India. The conference will discuss ensuring safer drugs reach the market through analyzing developments in pharmacovigilance, drug safety, and risk management. It will feature keynote speakers from various pharmaceutical companies and overviews of the latest challenges and opportunities in pharmacovigilance. The event aims to provide a platform for stakeholders to discuss best practices and advancing pharmacovigilance in India.
Kishan Kumar completed a summer internship project at Ranbaxy Laboratories Limited to study the market potential of multi-vitamins and the antibiotic cefexime. The project involved two tasks - understanding doctors' perceptions when prescribing multi-vitamins and cefexime, and analyzing the market potential of these products when sold over-the-counter versus through prescriptions. Kumar conducted surveys of doctors and retailers to gather data for the analysis. The goal of the project was to help Ranbaxy better understand opportunities in these therapeutic areas.
Contract Research Organisations- CRO in Pharma FieldVINOTH R
The document provides an overview of contract research organizations (CROs). It discusses that CROs were originally formed to help pharmaceutical companies deal with capacity issues and excess demand. CROs now provide a wide range of clinical trial and drug development services to pharmaceutical sponsors. They have become an important partner for both large pharmaceutical firms and smaller biotech companies. However, the Indian CRO industry still faces challenges such as financial issues, a lack of accredited trial sites, and regulatory hurdles.
Clinical research involves organized studies on human subjects to evaluate the safety and efficacy of new drugs, medical devices, and other therapies. It is a critical part of the drug development process, accounting for two-thirds of the total time and costs. India has become an attractive location for clinical research due to its low-cost yet skilled workforce, large patient populations, and established expertise in pharmaceuticals and business processes. The clinical research sector in India is growing rapidly, driven by global outsourcing trends and capabilities within the Indian pharmaceutical industry.
The document discusses bioprinting patents and intellectual property issues. It notes that while bioprinting techniques have been patented for years, the patenting of bioprinted tissues and organs is more limited as they lack expression, ornamental features, or source of origin. Utility patents provide the best protection for bioprinting innovation, though patents are difficult to obtain and enforce. Regulatory approval for bioprinted tissues is also expensive and time-consuming, providing little incentive for development without patent protection. The article examines patents covering the three phases of bioprinting and exceptions for experimental use.
Here are some key facts and figures about the global pharmaceutical industry:
- The global pharmaceutical market was estimated to be worth around $1.2 trillion in 2020. It is projected to reach $1.6 trillion by 2026.
- The top 10 global pharmaceutical companies by revenue in 2020 were Johnson & Johnson, Pfizer, Roche, Sanofi, Novartis, Merck & Co., AbbVie, GSK, Amgen, and Gilead Sciences.
- The top three pharmaceutical markets by sales in 2020 were the US at $360 billion, China at $145 billion, and Japan at $102 billion.
- The US accounted for around 40% of global pharmaceutical spending in 2020, despite
This document is a project report submitted by Mr. Santosh Panchakshari Salgare to the Department of Management Sciences at Savitribai Phule Pune University. The project involved conducting a study to understand the prescription pattern of generic drugs at Hindustan Antibiotics Limited in Pimpri, Pune. The report includes an introduction to the pharmaceutical industry, company profile of Hindustan Antibiotics Limited, objectives, methodology, findings and analysis of the study, and conclusions and recommendations.
Pharmaceutical, Bulk Drugs and Medicine Manufacturing Industry (Production, F...Ajjay Kumar Gupta
Quality control and quality assurance are vital in this industry. Many production workers are assigned full time to quality control and quality assurance functions, whereas other employees may devote part of their time to these functions. For example, although pharmaceutical company sales representatives, often called detailers, work primarily in marketing, they engage in quality control when they assist pharmacists in checking for outdated products.
Advances in manufacturing processes are also impacting the industry. While pharmaceutical manufacturers have long devoted resources to new drug development as a source for future profits, firms are increasingly realizing that improvements throughout the drug pipeline are needed to stay competitive.
See more
http://goo.gl/1sQLwS
http://goo.gl/jajeNa
http://goo.gl/0tvlst
http://www.entrepreneurindia.co/
Tags
Pharmaceutical Technology Books, Essentials of Pharmaceutical Technology, Pharmaceutical Technology, Pharmaceutical books, Science, Technology & Medicine Books, Drugs technology books, Drug and Pharmaceuticals technology book, Best small and cottage scale industries, Bulk Drugs Formulation, Bulk Drugs Manufacturing Industry, Business consultancy, Business consultant, Business guidance for Pharmaceutical industry, Business guidance to clients, Business Plan for a Startup Business, Creating a Pharma Start-up, Drug formulation manual, Formulation of Antibiotics, Formulation of Paracetamol, Formulation of Tablets, Great Opportunity for Startup, How to Start a Medicines manufacturing business?, How to start a pharmaceutical company, How to Start a Pharmaceutical Product Business, How to Start a Pharmaceutical Production Business, How to start a pharmacy business, How to start a successful drugs making business, How to start Antibiotics manufacturing business, How to start drugs pharmaceutical business, How to start medicine business, How to Start Medicine Manufacturing Industry in India, How to start medicine manufacturing, How to start Paracetamol production business, How to Start Pharmaceutical Manufacturing Company in India, Invest to setup a pharmaceutical business, Manufacturing of medicinal products- Pharmaceutical industry, Medicine Manufacturing Industry, Medicines Making Small Business Manufacturing, Modern small and cottage scale industries, Most Profitable Bulk Drugs production Business Ideas, New small scale ideas in Pharmaceutical industry, Pharma Manufacturing, Pharmaceutical and Medicines production Business, Pharmaceutical Based Profitable Projects, Pharmaceutical Based Small Scale Industries Projects, Pharmaceutical Drug Formulation, Pharmaceutical Drug Manufacturing Business, Pharmaceutical formulation guidelines, Pharmaceutical formulation, Pharmaceutical industry in India, Pharmaceutical industry, Pharmaceutical manufacturing Industry in India, Pharmaceutical Manufacturing Industry, Pharmaceutical Projects,
The document discusses career opportunities in chemistry after completing a BSc degree. It outlines higher studies options such as MSc degrees in various fields of chemistry and PhD programs. Careers are available in pharmaceutical, chemical, and other industries as analytical chemists, materials technologists, production chemists, and more. Government jobs are also available. The Indian chemical and pharmaceutical industries are large and growing, offering many employment opportunities for chemistry graduates in areas like manufacturing, quality control, research and development, and regulatory affairs. Skills in analytical techniques, spectroscopy, and chromatography are useful for jobs in quality testing.
The document discusses the current state of clinical trials in India. It begins by describing how India was projected to become a global center for clinical research by 2012 due to several favorable factors, including large patient populations and lower costs. However, since 2009 there has been a dramatic 50% drop in successfully conducted international clinical trials in India. A key reason for this is that the quality of trials, investigators, and data in India has been challenged. For clinical trials to be conducted flawlessly, investigators need proper training and expertise, which is lacking in India currently. The regulatory system in India also needs improvement, such as implementing a rigorous review process of new drug applications similar to other countries. Addressing issues around quality and documentation is also important to
1) Regulatory affairs professionals play important roles in coordinating scientific efforts with regulatory needs throughout a product's lifecycle. They help companies reduce time to market and maximize resources.
2) Key responsibilities include evaluating marketing applications, issuing approvals, developing guidelines, inspecting sites, and monitoring drug safety.
3) In the pharmaceutical industry, regulatory affairs professionals develop regulatory strategies, prepare applications, maintain relationships with health authorities, and ensure compliance.
Pharmaceutical Offshoring Landscape A Syndicated Reportshekhar619
- The pharmaceutical industry is increasingly offshoring R&D activities to countries like India and China to take advantage of lower costs. India captured $125 million in offshored R&D spending in 2008 and China captured $375 million.
- India has become a major destination for clinical trials and data management due to its large, skilled talent pool and lower costs that are 20-30% of developed markets. The market for outsourced clinical trials in India is growing at 31% annually.
- Pharmaceutical companies are establishing facilities in India's Special Economic Zones which provide tax incentives and regulatory benefits to encourage further offshoring and foreign investment in the country.
“LET US KNOW ABOUT QUALITY BY DESIGN IN PHARMACEUTICAL INDUSTRY”Rajatmishra137
The Impression of Quality by configuration protects by demonstrating that quality is simply not a demonstration, yet it is a propensity. As of late Quality by structure (QbD) has increased a lot of consideration among the pharmaceutical business in extremely short course of time . It goes about as a connection between the business and medication administrative specialists for example (FDA), which is predominantly founded on logical, chance based, all encompassing and proactive methodology for advancement of pharmaceutical item. QbD has helped in making the new detailing, and furthermore the structuring of new method of medication conveyance, just as the better approaches for assembling procedure, and attempts to guarantee the predefined quality items . Key attributes of QbD are that it gives an apparatus to centered and effective medication improvement. It is pertinent to diagnostic strategies. Key components of the Quality by configuration are The Quality Target Product Profile (QTPP), Critical Quality Attributes (CAQ), Design space, Control procedure, lifecycle the executives . Use of value by configuration is in different new looks into dependent on HPLC technique, and we give quit estimation of medication conveyance as indicated by the patients BMR , additionally in Quality by Design in Biopharmaceuticals .
7th Pharmacovigilance 2014 “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management" 21st November 2014, Kohinoor Continental Hotel, Mumbai, India Greetings from Virtue Insight, I am happy to invite you and your colleagues to be a sponsor / delegate for our upcoming conference. The “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management” at 7th Pharmacovigilance 2014 on 21st November 2014, Kohinoor Continental Hotel, Mumbai, India.Contact:-Tel: +91 9677590192 Email: dinesh@virtueinsight.co.in
The document provides information about the 7th Pharmacovigilance conference taking place on November 21st, 2014 in Mumbai, India. The conference will discuss ensuring safer drugs through analyzing developments in pharmacovigilance, drug safety, and risk management. Key speakers from various pharmaceutical companies will discuss topics like signal detection, risk management plans, data collection and management, and regulatory expectations and updates. The conference is aimed at professionals in pharmacovigilance, drug safety, clinical research, and regulatory affairs. It will provide a platform for stakeholders to discuss best practices and challenges in the field.
I am writing to make you aware of our upcoming event:- 7th Pharmacovigilance 2014 taking place on 21st November 2014, Kohinoor Continental Hotel, Mumbai, India.
0601017 explore market opportunities for new product launchSupa Buoy
Hi Friends
This is supa bouy
I am a mentor, Friend for all Management Aspirants, Any query related to anything in Management, Do write me @ supabuoy@gmail.com.
I will try to assist the best way I can.
Cheers to lyf…!!!
Supa Bouy
Similar to Global Pharmaceuticals R&D Programme (20)
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...my Pandit
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
buy old yahoo accounts buy yahoo accountsSusan Laney
As a business owner, I understand the importance of having a strong online presence and leveraging various digital platforms to reach and engage with your target audience. One often overlooked yet highly valuable asset in this regard is the humble Yahoo account. While many may perceive Yahoo as a relic of the past, the truth is that these accounts still hold immense potential for businesses of all sizes.
3 Simple Steps To Buy Verified Payoneer Account In 2024SEOSMMEARTH
Buy Verified Payoneer Account: Quick and Secure Way to Receive Payments
Buy Verified Payoneer Account With 100% secure documents, [ USA, UK, CA ]. Are you looking for a reliable and safe way to receive payments online? Then you need buy verified Payoneer account ! Payoneer is a global payment platform that allows businesses and individuals to send and receive money in over 200 countries.
If You Want To More Information just Contact Now:
Skype: SEOSMMEARTH
Telegram: @seosmmearth
Gmail: seosmmearth@gmail.com
Industrial Tech SW: Category Renewal and CreationChristian Dahlen
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdf
Global Pharmaceuticals R&D Programme
1. Informedia proudly presents the inaugural
conference on
For more details, visit www.globalpharma-summit.com
Best Practice in Service Outsourcing
Conference: 3rd - 4th December 2008 | Venue: Hotel J W Marriott, Mumbai
Global Pharmaceuticals
Research & Manufacturing India 2008
Global Pharmaceuticals
Research & Manufacturing India 2008
n
nActis Biologics
nAll India Institute of
Medical Sciences
nAmgen India
nAstraZeneca Pharma
nCadila Pharmaceuticals
nDr Reddy's Laboratories
nEisai India
nEli Lilly &Co.
nEvolva Biotech
nFDA Maharashtra State
nGlaxoSmithKline
Pharmaceuticals
nInstitute of Clinical
Research India
nNishith Desai Associates
nNovartis
nNycomed Pharma USA
nPfizer
nSandoz
nSanofi–Aventis
nTakeda Global Research
and Development
nUSV
nWockhardt
nWyeth
nZydus Cadila
Abbott India
Top Level Speakers from
Ü
Ü
Ü
Ü
Ü
Find out how to outsource your clinical trials to India
Harness the benefits of Indian CRAMS/CSOs within the
current global pharma business model
Evaluate the implications of moving global R&D offshore
to India
Examine the influence and input of biotech companies in
the Indian pharma market
Learn about the emerging and innovative business
models for partnerships and collaboration
Key Note Speakers
Mr Ranga Iyer
President OPPI and
Managing Director
Wyeth
Mr Suhas Chaudhari
Joint Commissioner
(Greater Mumbai)
FDA Maharashtra State
Uma Nandan Misra
Vice President -
Operations & Site Manager
AstraZeneca Pharma
Mr Ranjit Shahani
Vice Chairman,
Managing Director
and Country President
Novartis
Mr Harjit Singh,
Senior Development
Manager,
Takeda Global Research
and Development, UK
Principal
Media Partner
Media Partners
Online Media Partners
International
Media Partner
2. 10.00 am Evaluating the implications of moving global R&D
offshore vs outsourcing to India
Globalisation of drug development processes
What impact will Indian CROs have on shaping the
global R&D landscape?
Indian CROs view on the offshoring operations -
how do they view their interaction and experiences
when working with US and European pharmas?
l
m
m
Dr Chandrashekhar Potkar
Managing Director, Clinical Research
Pfizer
8.30 am Registration
9.00 am Chairman's Welcome and Opening Address
9.35 am Harnessing the benefits of Indian CRAMS/CSOs
within the current global pharma business model
Comparing CRO (Contract Research Organisation) and
CM (Contract Manufacturing) activities within India,
externally and looking at prospects for future
development
Retrospective analysis of how the CRAMS/CSOs
business model has evolved - where we are now?
Analysis of the long-term prospects for the
CRAMS/CSOs industry and its ultimate effect on
the Indian pharma business
l
m
m
Dr Ish Khanna
Dr Reddy's Laboratories USA
Mr Ranjit Shahani
Vice Chairman, Managing Director and
Country President
Novartis
9.10 am Overview of the Indian pharma sector in an
economic context
What is the current development status of the
industry?
Is the cost advantage of investing in India now
diminishing because of escalating operating costs?
Dealing with the declining ROI of pharma
businesses - proposed solutions to maintain
sustainable growth of the industry
Indian pharma in comparison to other emerging
markets: China, South East Asia and Latin America
Evaluating offshore process outsourcing from a
regulatory and cost perspective
Predicting future prospects: how the Indian economy
is expected to develop - where will we be in 2020?
l
m
m
m
m
l
Globalisation of the Indian pharma industrySession I:
Wednesday 3rd December, 2008DAY 1:
2.40 pm Three years on from the Indian Patents Act 2005
Myths about patents
Features of the Act
Unfinished agenda
Path forward
l
l
l
l
Mr Ranga Iyer
President, OPPI and Managing Director
Wyeth
3.05 pm Pharmacovigilance, PMS and PSUR in India:
Current status and the road map. Assessing the
development of methodologies for monitoring
drug safety
Addressing the increasing concerns over drug safety
and post-approval surveillance
Ensuring proactive pharmacovigilance throughout
the product lifecycle
Improving patient safety by increasing the
transparency of safety data
Transferring the pharmacovigilance advancements of
the West to emerging markets
Exploring the relationship between
pharmacovigilance and risk management
l
l
l
l
l
Mr YK Gupta
Head, Department of Pharmacology,
Zonal Pharmacovigilance Centre
All India Institute of Medical Sciences
10.25 am Morning Refreshments & Networking Break
11.20 am The evolving regulation landscape in India
Discussing the current Indian regulatory environment
Recognising the requirements of Indian regulations
towards approval of drugs developed
Ensuring effective protection of intellectual property
rights and development processes
Standard operating procedures for conducting clinical
trials in India - Schedule Y of the Drugs and Cosmetics
Act in India and guidelines for biomedical research
l
l
l
l
Dr Surinder Singh
Drugs Controller General of India
*
Mr Suhas Chaudhari
Joint Commissioner (Greater Mumbai)
FDA, Maharashtra State
10.55 am Harmonisation of the global pharma regulatory
environment
Evaluating the impact of globalisation on the pharma
regulatory landscape and how this will affect research
and manufacturing processes
Finding a common set of regulations which are
acceptable to all countries
l
l
Indian and worldwide regulatory policies
and legislative framework
Session II:
2.00 pm The viewpoint from two industry specialists on
managing legal and regulatory considerations in
clinical outsourcing
The patent regime and present status of R&D in
India
Government initiatives to shorten the clinical
trials application time
Clinical research landscape in India
Discussing the market prospects for further
development
Analysing the reason for the gap in the amount of
research between India and the rest of the world
Investigating pharmacovigilance practices in India
for the clinical trials market and for future REITs
l
m
l
m
m
l
Dr SK Gupta, Director General
Institute of Clinical Research India
Ms Gowree Gokhale, Partner
Nishith Desai Associates
www.globalpharma-summit.com
For an Updated Conference Programme,
Please log on to:
* Awaiting final confirmation
12.30 pm Luncheon
11.45 am SPEED NETWORKING
The quicker way to do business
3rd - 4th December, 2008
Global PharmaceuticalsGlobal Pharmaceuticals
Research & Manufacturing India 2008
3. 3.30 pm
Dr Sham Nikam, Chief Scientific Officer
Nycomed Pharma USA
Evaluating the current status of drug R&D in India
Drug discovery in India, along with CROs in Indian
pharma industry
Exploring the contract research market from
preclinical to phase 3
Emerging opportunities for conducting exploratory
proof-of concept studies
Trends on outsourcing drug discovery and
development (DD&D)
Producing cost-effective NCEs (New Chemical
Entities) targeting lifestyle, resistant infectious
diseases with improved efficacy and minimal side
effect
Producing a pipeline of promising drug candidates
- DD&D and NCEs
l
m
m
l
m
m
4.15 pm
Dr PM Murali, Managing Director
Evolva Biotech
Building an indigenous value based ecosystem for
cost effective drug discovery in India. Six key
aspects leading to a sub half billion dollar NDA in
the future Indian discovery landscape
INVESTMENT: Arrival of startup VCs redefining the
discovery landscape in India – those with longer
acceptable incubation periods for their ROI and a
higher risk taking ability
EXPERTISE: Influx of returning Indians from
elsewhere with prior experience in drug discovery and
development
FACILITIES: Availability of world class CRAMS/CSOs in
biology, chemistry and pharmacology
RESEARCH CONSULTANTS: Networking with scientific
clusters of excellence, who are willing to collaborate
with industry
INTERFACE & SCALEUP OPERATIONS: English
speaking population and FDA approved facilities –
both available with largest numbers outside United
States
CLINICAL TRIALS: Huge patient population with
diversity and CSIR's efforts in systematic mapping
of heterogenicity, enables effective clinical trials,
pharmacogenomics and pharmacovigilance
l
l
l
l
l
l
Dr Veena Jaguste, Director, Global Development
Operations, Amgen India
4.40 pm The impact of outsourcing on drug development
performance and implications for more effective
collaboration with CROs
Clinical research and trials outsourcing - overcoming
challenges and impediments
Incorporating emerging regions into clinical
development plans - a unique set of opportunities and
challenges
l
l
Mr Harjit Singh, Senior Development Manager
Takeda Global Research and Development UK
5.05 pm Clinical research and trials outsourcing -
challenges and hurdles in India
Conducting phase 1 and 2 clinical trials in India
Clinical quality assurance and its significance in global
drug registration
Clinical safety and risk evaluation in trials
Conducting ethical clinical trials
Managing clinical trial sites successfully
Feasibility studies for investigational site selection
Non clinical: technical and operational procedures and
how to address them
l
l
l
l
l
l
l
3.55 pm Afternoon Refreshments & Networking Break
Mr Sanjeev Saxena
Chairman and CEO
Actis Biologics
Evaluating the influence and input of biotech firms
on the Indian pharma market
Evaluating global biotechnology development and
India's role in the process
Ensuring global biotech opportunities within India and
overseas
Gaining advantage of innovative bio-technologies
Forming partnerships with Indian biotech firms
l
l
l
l
9.10 am
Thursday 4th December, 2008DAY 2:R&D in India: the landscape of opportunities
and challenges
Session III:
8.30 am Registration
9.00 am Chairman's Opening Remarks
Emerging trends in biotechnologySession IV:
Benefits of contract manufacturing
for Indian producers
Session V:
10.40 am Morning Refreshments & Networking Break
9.35 am
Mr Subash Kapre *
Executive Director
Serum Institute of India
Key issues affecting biopharmaceutical
manufacturing
Manufacturing biologics from the CMO (Contract
Manufacturing Organisation) perspective
Where is biopharma manufacturing going in the next
10 years?
Regulatory initiatives impacting biopharmaceutical
development and manufacturing
Entry of biosimilar and bio-generic products
Ensuring quality and safety in bio-processes
Strategies for ensuring product comparability and
safety after manufacturing process changes
l
l
l
l
l
m
10.00 am Global harmonisation and the perception of Indian
CM to the rest of the pharma industry
Evaluating international trends and global
harmonisation opportunities
CMO management throughout the relationship
between CMO and outsourcer lifecycle
Obtaining and understanding how process changes can
affect the structure and biological activity of the final
product (in technology transfer)
Implementing successful approaches in manufacturing
Evaluating the role of globalisation on the regulatory
landscape and manufacturing process
Contract manufacturing - in house vs outsourcing
Emerging fields in the pharma outsourcing market -
why should you outsource manufacturing and risk
costly technology transfer delays?
A critical assessment of the current manufacturing
outsourcing strategies
l
l
l
l
l
l
l
l
Mr Sanjit Lamba, President and CEO
Eisai India
Mr Lakshminarayana Neti, Director Operations
Abbott India
For enquiries write to
jayesh.kanaskar@informedia-india.com5.40 pm Informedia’s Cocktail Reception
5.30 pm Chairman's Closing Remarks and End of Day One
* Awaiting final confirmation
3rd - 4th December, 2008
Global PharmaceuticalsGlobal Pharmaceuticals
Research & Manufacturing India 2008
4. Mr Uma Nandan Misra
Vice President, Operations and Site Manager
AstraZeneca Pharma
11.50 am Case Study - Achieving operational excellence in
a pharma manufacturing plant
Cultural transformation
Aligning manufacturing priorities with business
Identifying & monitoring critical performance
parameters
Engaging all employees for continuous improvement
Achieving excellence in focussed areas
l
l
l
l
l
12.55 pm Luncheon
2.10 pm Implementing strategies to ensure that the
contractors comply with quality agreements
Compliance with GMP requirements
Demonstrating how cGMP is essential for survival in
the pharma business
Gain a competitive edge with a GMP compliant
designed facility
Learn the importance of well written procedures,
validation, documentation and SOPs for cGMP
compliance
l
m
m
m
Dr PM Naik
Project Director
Zydus Cadila
Evolving partnering and business modelsSession VI:
2.35 pm Implementation of risk management strategies in
outsourced manufacturing
Risk and risk management in pharmaceutical and
biopharmaceutical outsourcing
Measuring risk as a preventative technique -
ensuring operational excellence
Identifying, understanding and rating risk
throughout all processes
Implementing effective methods to avoid risk
Identifying and overcoming cost issues in CM
outsourcing
l
l
m
m
m
Mr TS Anand
Director, Contract Manufacturing and Outsourcing
Dr Reddy's Laboratories
3.00 pm Innovative models of collaborating opportunities
with CRAMS/CSOs
Different models of collaboration that can be
established between Indian firms and MNCs
New business and partnership models evolving in
India
In and out licensing of drug discovery research
Partnering opportunities - strategic involvements
l
l
l
l
Ms Mukta Arora
Head of Global Sourcing
Eli Lilly & Co.
3.45 pm External sourcing in the pharma space
Requirements for external sourcing
Basic aspects of external sourcing
Challenges faced by the Indian pharma business as
compared to international businesses and other
sectors
How do you choose the right partner?
Relationship building for the longer term - an essential
part of the pharma business
Legal and contractual issues
l
l
l
l
l
l
Mr Debabrata Gupta
Director and Chief Operating Officer
USV
4.45 pm
4.35 pm
End of Day Two and Close of the Conference
Chairman's Closing Remarks
4.10 pm What are the strengths that the outsourcing
organisation is looking for while selecting the
CRAMS/CSOs?
What the contract givers and contract acceptors
should be aware of to continue long-term business
relationships
Who is the owner of the intellectual property
developed during the cooperation and why?
How to face audits from the outsourcing organisation
to get approved as a CSO
Why continuous communication is essential in such a
relationship
Why the customer should be kept informed of the
failures and mistakes that take place
At what stage does the product need to be optimised
during CRO or CSO?
How process changes from established practice could
affect the customer and the relationship
l
l
l
l
l
l
l
Dr Sunil Kanvinde
Deputy General Manager, Technical Services
Sandoz
11.10 am Two key opinion leaders demonstrate how to
establish successful technology transfer in CMO
to ensure an effective manufacturing process
Technology transfer for outsourcing and contract
manufacture
Implementing technology transfer to ensure an
effective manufacturing process
Critical factors and timelines for a successful
technology transfer
Success factors during process comparability and
validation
Developing and implementing clear quality
agreements with CMOs
Incorporating knowledge to ensure process
comparability, validation and GMP requirements
l
l
l
l
l
l
Mr KK Ambardar, General Manager,
Contract Manufacturing, Cadila Pharmaceuticals
Dr Ashoke Banerjee, Executive Director
GlaxoSmithKline Pharmaceuticals
12.15 pm Panel Session:
Two industry leaders viewpoint on quality
management - developing and implementing
sustainable quality agreements with CMOs
What are the ‘rules of engagement’ between the
sponsor and client for proper management of mutual
quality and quality-regulatory needs in an outsourcing
arrangement?
One size does not fit all - How to design and put a
workable and sustainable quality management system
into practice?
How does a quality agreement separate or link to other
agreements like commercial and technical?
What are the regulatory and legal requirements that
should be addressed in a quality agreement?
How should critical quality activities of change
management, deviations, investigations, product
release, GMP audits and regulatory inspections be
integrated in to a good quality agreement?
l
l
l
l
l
Mr Satish Rajkondawar, Senior Director,
External Manufacturing Site, Sanofi-Aventis
Mr Viswajit Sahu, DGM Contract Manufacturing
Services, Wockhardt
3.25 pm Afternoon Refreshments & Networking Break
3rd - 4th December, 2008
Global PharmaceuticalsGlobal Pharmaceuticals
Research & Manufacturing India 2008
5. About Informedia
Informedia India Pvt Ltd is a leading conference organiser
which specialises in professional high level business
conferences targeted at senior management in a number of
industry sectors. We are a subsidiary company of the
Expomedia Group Plc., a leading International media group
with offices in 13 countries worldwide.
Dedicated to in-depth research, our conferences provide you
with relevant information about what you want to know, when,
and from whom. Straightforward and industry oriented, our
conferences are a very time efficient way to gain a head start
and secure your competitive advantage. Our focused events
create a platform to network with both new and experienced
peers from various industries and feature the most relevant
case scenarios in order to equip you with valuable knowledge
and current know-how.
www.informedia-india.com
Attracting the industry's most powerful and influential delegates
àBusiness Development
àClinical Research Outsourcing
àManufacturing
àDrug Discovery & Development
àMedical Affairs
àPharmaceutical Development
àPharmacoviligance
àPreclinical Development
àProcurement
àProduction Planning & Manufacturing
àPurchasing
àQuality Control & Assurance
àRegulatory Affairs
àRisk & Safety Assessment
Heads of Divisions
àCXOs
àProject Directors
Who will be there?
The Global Pharmaceuticals conference has been
developed with the following executives in mind:
Which industry sectors should attend?
àPharmaceutical Companies
àBiotech Companies
àCROs and CMOs
àPharmaceutical Manufacturers
àResearch Laboratories and Institutes
àBusiness Consulting Firms
àGovernment Institutions and Regulators
àPrivate Equity Funds
àVenture Capitalists
Sponsorship...
helps you to do business and deliver your message to the Global Pharmaceutical market.
Contact our Sponsorship Director on sponsorship@expomediagroup.com or
call +91 22-28500104 in India and +44 (0) 1923 491 067 in the UK to tailor your package
Q.1 Could you benefit from presenting a case study or hosting a
workshop in front of your target audience and demonstrating
your expertise?
If your answer is yes to any of these questions then the
Global Pharmaceuticals Research and Manufacturing India 2008 is
the most important place for you to be.
6 simple questions to determine value from sponsorship
Q.2 Do you want to do business with senior decision makers from
the leading Pharmaceutical and Biotech companies from
India, Asia and the rest of the World?
Q.3 Can you benefit from the impact of outsourcing on Clinical
Research or Contract Manufacturing?
Q.4 Can you provide a solution to the bad perception of
manufacturing from a CMO's perspective?
Q.6 Do you want to collaborate on drug development
performance with CRO's?
Q.5 Are you able to demonstrate the best way to run effective
proof of concept trials?
Sponsoring the Global Pharmaceuticals Research and
Manufacturing India 2008 forum will enable you to:
Raise your company’s profile
Increase your chances of being chosen as the logical choice of
supplier, when they hear and see you can exceed their needs.
Don't pass business opportunities by, whilst your competitors
walk away with them.
Find your all year round marketing solution
There are a limited number of opportunities for you to get
your message across to the leading International
Pharmaceutical and Biotechnology Companies, so act now to
avoid disappointment.
Put simply, you can't afford to miss out!
The conference helps you to overcome common business
development hurdles, like access and face to face networking
with the right people with hours of scheduled networking
time. Global Pharmaceuticals will put you face to face with
people that matter in this industry.
Join our existing partners at this prestigious event
6. REGISTRATION FORM HOTEL INFORMATION
Hotel J W Marriott
www.globalpharma-summit.com
I / We / would like to attend / nominate the following
Please tick
I enclose my Cheque/Draft payable to
INFORMEDIA INDIA PVT. LTD. by post at
204-205, Town Centre, Andheri-Kurla Road,
Sakinaka, Andheri (E), Mumbai - 400059
I am paying by bank transfer (copy attached)
I cannot attend this event but
I would like to purchase the Conference
Documentation for Euro 150 + 12.36 %
Service Tax
Please do not include me on your mailing list
REGISTER NOW in 3 Easy Steps
Call: Sarfraz Patel
Cell: +91 98 33487628
Tel: +91 22 40820183
Fax: +91 22 28509590
Register Online
www.globalpharma-summit.com
1
2
3
Delegate 1 Delegate 2 Delegate 3
Designation
Tel/Mobile/Fax
Email ID
Organisation
Address
Approving Authority
Name
Pin Code
Name/
Designation
Signature
Feesareinclusiveofallprogrammedocuments,lunchonbothconferencedaysandrefreshments.Thefeesdo
not cover travel and accommodation costs. Following completion and return of the registration form
including the authorized signature, full payment is required within 5 working days from receipt of invoice.
PLEASE NOTE: payment must be received prior to the conference date. Admission to the event cannot be
guaranteedifthepaymenthasnotbeenreceivedbyInformediaIndiaPvt.Ltd.
Provided the total fee has been paid, substitutions can be made at any time free of charge. Cancellations
must be received in writing bymail or fax 5 working days before the conference in order to qualify for a Credit
Note which will be valid for 6 months after the date of issue. Thereafter, a Credit note cannot be issued.
Nonpaymentornon-attendancedoesnotconstitutecancellation.If,foranyreason,InformediaIndiaPvt.Ltd.
decides to cancel or postpone this conference and / or workshop/s, Informedia India Pvt. Ltd. is not
responsibleforcoveringairfare,hotelorothertravelcostsincurredbythedelegate.Incaseofcancellationor
postponement, the fee qualifies for a credit note equal in value for any future event organized by Informedia
IndiaPvt.Ltd.
All Intellectual Property Rights in all materials produced or distributed by Informedia India Pvt. Ltd. in
connectionwiththiseventisexpresslyreservedandanyunauthorizedduplication,publicationordistribution
isprohibited.
Event programme content and the event venue can be subject to change without notice and does not impact
theTermsandConditionsspecifiedin1.and2.
With his or her signature, the delegate acknowledges that they have read and understood all terms of this
contractincluding,withoutlimitation,theprovisionsrelatingtocancellationandtopaymentterms.
Terms & Conditions
1.
2.
3.
4.
Please note that 12.36% service tax will be applicable on the above mentioned fees
Fees Package
Euro 1,399Euro 899
For International DelegatesFor Indian Delegates
Conference: 3rd - 4th December 2008 | Venue: Hotel J W Marriott, Mumbai
Juhu Tara Road,
Mumbai - 400 049, India
Tel: +91 22 66933000
Fax: +91 22 66933100
www.marriott.com
Best Practice in Service Outsourcing
Global Pharmaceuticals
Research & Manufacturing India 2008
Global Pharmaceuticals
Research & Manufacturing India 2008